.png)
_(1).png){kind=logo}
Scoping Review SGLT-2 Inhibitor Efektif dalam Menurunkan Albuminuria pada Pasien Diabetes Melitus Tipe 2
Abstract
Diabetes melitus (DM) merupakan penyakit tidak menular dengan insidensi terus meningkat setiap tahunnya. Salah satu komplikasi DM tersering adalah nefropati diabetik yang ditandai dengan albuminuria. Sodium glucose co-transporter (SGLT-2) inhibitor merupakan golongan obat antidiabetik yang bersifat insulin independen dan diharapkan menurunkan kejadian kerusakan fungsi ginjal. Kurangnya penelitian dan informasi obat golongan ini di Indonesia menyebabkan peneliti melakukan penelitian dengan tujuan mengetahui efektivitas pemberian obat golongan SGLT-2 inhibitor pada pasien DM tipe 2 terhadap penurunan kejadian albuminuria. Metode yang digunakan dalam penelitian ini adalah scoping review, dengan bahan penelitian artikel dari jurnal internasional yang memenuhi kriteria inklusi dan eksklusi. Artikel ini kemudian diseleksi menggunakan diagram PRISMA dengan mempertimbangkan Population (DM tipe 2), Intervention (pemberian SGLT-2 inhibitor), Comparison (plasebo atau anti diabetik lain), Outcome (penurunan albuminuria), Study (RCT dan Cohort retrospective). Didapatkan dari 13 artikel bahwa obat SGLT-2 inhibitor yang digunakan bervariasi yaitu canagliflozon (6), empagliflozin (3), dapagliflozin (2), ertugliflozin (2), dan yang tersering digunakan adalah canagliflozin ditemukan pada 6 artikel (50%). Golongan obat SGLT-2 inhibitor memiliki kecenderungan yang sama, dapat ditoleransi dengan baik dan efektif dalam menurunkan kejadian albuminuria melalui mekanisme perubahan hemodinamik ginjal, dengan urin albumin-kreatinin rasio (UACR) sebagai parameter.
Scoping Review
SGLT-2 Inhibitors Effective to Reduce Albuminuria in Type 2 Diabetes Mellitus
Diabetes mellitus (DM) is a non-communicable disease with an increasing incidence every year. One of the most common complications of DM is diabetic nephropathy which is characterized by albuminuria. Sodium-glucose co-transporter (SGLT-2) Inhibitors is a class of anti-diabetic drugs that are insulin-independent and expected to reduce the incidence of impaired kidney function. The aim of this study was to ensure the effectiveness of SGLT-2 inhibitor drug administration in type 2 DM patients to reduce the incidence of albuminuria. The method used is scoping review, with research articles from international journals sorted by the inclusion and exclusion criteria. These articles was selected using the PRISMA diagram by considering Population (DM type 2), Intervention (administration of SGLT-2 inhibitors), Comparison (placebo or other anti-diabetic), Outcome (decreased albuminuria), Study (RCT and retrospective cohort). It was obtained from 13 articles that the SGLT-2 inhibitor drugs used varied, canagliflozon (6), empagliflozin (3), dapagliflozin (2), ertugliflozin (2), and the most commonly used was Canagliflozin found in 6 articles (50%). The SGLT-2 inhibitor class of drugs has the same tendency, well-tolerated, and effective in reducing the incidence of albuminuria through the mechanism of renal hemodynamic changes, with urine albumin-to-creatinine ratio (UACR) as a parameter.
Keywords
Full Text:
PDFReferences
WHO. Global Report on Diabetes. Isbn. 2016;978:6-86. [diunduh 14 Oktober]. Tersedia dari: http://www.who.int/about/licensing/.
Kementerian Kesehatan RI. Cegah dan kendalikan dengan cerdik dan patuh. 2018:6-8.[diunduh 18 oktober 2019] tersedia dari : http://www.depkes.go.id/article/print/18030700007/cegah-dan-kendalikan-penyakit-ginjal-dengan-cerdik-dan-patuh.html.
Nazar CMJ. Diabetic nephropathy; principles of diagnosis and treatment of diabetic kidney disease. J nephropharmacology. 2014;3(1):15-20. [diunduh 27 Januari 2020]. tersedia di : http://www.ncbi.nlm.nih.gov/pubmed/28197454%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5297588.
Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. 2014;5(2):355–66.
Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–51. [diunduh 11 oktober 2020] Tersedia dari : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166348/
Takashima H, Yoshida Y, Nagura C, Furukawa T, Tei R, Maruyama T, et al. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Diabetes Vasc Dis Res. 2018;15(5):469–72. [diunduh 16 november 2020]. tersedia di https://journals.sagepub.com/doi/full/10.1177/1479164118782872
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–306. [diunduh 16 november 2020]. tersedia di https://www.nejm.org/doi/full/10.1056/nejmoa1811744
Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. Diabetes Ther [Internet]. 2018;9(5):1757–73.Tersedia dari: https://doi.org/10.1007/s13300-018-0471-8
Petrykiv SI, Laverman GD, de Zeeuw D, Heerspink HJL. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes, Obes Metab. 2017;19(10):1363–70. [diunduh 16 november 2020]. Tersedia di https://pubmed.ncbi.nlm.nih.gov/28295959/
Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac. Lancet Diabetes Endocrinol. 2019;7(6):429–41. [diunduh 16 november 2020]. tersedia di https://pubmed.ncbi.nlm.nih.gov/30992195/
Cherney DZI, Heerspink HJL, Frederich R, Maldonado M, Liu J, Pong A, et al. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020;63(6):1128–40. [diunduh 18 november 2020]. tersedia di https://www.nejm.org/doi/full/10.1056/nejmoa1611925
Kadowaki T, Nangaku M, Hantel S, Okamura T, von Eynatten M, Wanner C, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME ® trial. J Diabetes Investig. 2019;10(3):760–70. [diunduh 18 november 2020]. tersedia di https://pubmed.ncbi.nlm.nih.gov/30412655/
Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol [Internet]. 2018;6(9):691–704. [diunduh 18 november 2020]. tersedia di http://dx.doi.org/10.1016/S2213-8587(18)30141-4
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323–34. [diunduh 18 november 2020]. tersedia di https://www.nejm.org/doi/full/10.1056/NEJMoa1515920
Nakamura A, Miyoshi H, Kameda H, Yamashita K, Kurihara Y. Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. Diabetol Metab Syndr [Internet]. 2020;12(1):1–6. [diunduh 18 november 2020]. tersedia di https://doi.org/10.1186/s13098-020-0516-9
Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28(1):368–75. [diunduh 18 november 2020]. tersedia di https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228910/pdf/125_2020_ Article_5133.pdf
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–57. [diunduh 16 november 2020]. tersedia di https://www.nejm.org/doi/full/10.1056/nejmoa1611925
Neuen BL, Ohkuma T, Neal B, Matthews DR, De Zeeuw D, Mahaffey KW, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program. J Am Soc Nephrol. 2019;30(11):2229–42. [diunduh 18 november 2020]. tersedia di https://pubmed.ncbi.nlm.nih.gov/31530577/
John P, Yadla M. Noninvasive method of differentiating diabetic nephropathy and nondiabetic renal disease using serum bone morphogenetic protein-7 and transforming growth factor-beta 1 levels in patients with type- 2 diabetes mellitus. Saudi J Kidney Dis Transpl. 2019;30(6):1300-1309. doi:10.4103/1319-2442.275474
Toth-Manikowski S, Atta MG. Diabetic kidney disease: Pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015. doi:10.1155/2015/697010 [diunduh 26 november 2020]. tersedia di https://www.hindawi.com/journals/jdr/2015/697010/
Lim AKH. Diabetic nephropathy – Complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361-381. doi:10.2147/IJNRD.S40172
Ley SH, Schulze MB, Hivert M-F, Meigs JB, Hu FB. Risk Factor for Type 2 Diabetes Melitus. Med clínica. 2015. 17;116(10):398-9. [monograph on the internet]. [diunduh 12 november 2019]. tersedia di : http://www.ncbi.nlm.nih.gov/pubmed/11333683.
Care D, Suppl SS. Classification and diagnosis of diabetes: Standards of medical care in Diabetesd2018. Diabetes Care. 2018;41(January):S13-S27. doi:10.2337/dc18-S002
Khairani. Hari Diabetes Sedunia Tahun 2018. Pus Data dan Inf Kementrian Kesehat RI. 2019:1-8. [diunduh 5 Desember 2019] Tersedia dari : https://pusdatin.kemkes.go.id/resources/download/pusdatin/profil- kesehatan-indonesia/Data-dan-Informasi_Profil-Kesehatan-Indonesia- 2017.pdf
Gripp KW, Ennis S, Napoli J. Exome Analysis in Clinical Practice: Expanding the Phenotype of Bartsocas-Papas Syndrome. Am J Med Genet Part A. 2013;161(5):1058-1063. doi:10.1002/ajmg.a.35913.
DOI: https://doi.org/10.29313/jiks.v3i1.7478
Refbacks
- There are currently no refbacks.
Jurnal Integrasi Kesehatan dan Sains is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.